We used Cox proportional hazard regression modeling to calculate hazard ratios (HRs) and 95% confidence intervals (CI) overall and stratified by BRCA1 and BRCA2 pathogenic variant status, family history of breast cancer, menopausal status, and estrogen receptor-positive (ER+) breast cancer.We observed 618 incident invasive or in situ breast cancers over a median 12.9years. Samples were frozen at -80 C, and DNA was extracted from them after 1 to 10 years. Such programs represent a major change to the financing and affordability of genetic testing. Aredo, J. V., Luo, S. J., Gardner, R. M., Sanyal, N. n., Choi, E. n., Hickey, T. P., Riley, T. L., Huang, W. Y., Kurian, A. W., Leung, A. N., Wilkens, L. R., Robbins, H. A., Riboli, E. n., Kaaks, R. n., Tjnneland, A. n., Vermeulen, R. C., Panico, S. n., Le Marchand, L. n., Amos, C. I., Hung, R. J., Freedman, N. D., Johansson, M. n., Cheng, I. n., Wakelee, H. A., Han, S. S. A Population-Based Study of Genes Previously Implicated in Breast Cancer. Overall, 1301 (43.9%) patients considered CPM (601 [24.8%] considered it very strongly or strongly); only 395 (38.1%) of them knew that CPM does not improve survival for all women with breast cancer. Staton, A. D., Kurian, A. W., Cobb, K., Mills, M. A., Ford, J. M. Magnetic resonance galactography: A feasibility study in women with prior atypical breast duct cytology. View details for DOI 10.1200/JCO.2014.57.0085, View details for Web of Science ID 000355999800009, View details for DOI 10.1001/jamaoncol.2015.28, View details for Web of Science ID 000358036900373, View details for DOI 10.1200/jco.2015.33.15_suppl.1513, View details for Web of Science ID 000358036900380, View details for Web of Science ID 000358036900228, To evaluate preferences for and experiences with genetic testing in a diverse cohort of patients with breast cancer identified through population-based registries, with attention to differences by race/ethnicity.We surveyed women diagnosed with nonmetastatic breast cancer from 2005 to 2007, as reported to the SEER registries of metropolitan Los Angeles and Detroit, about experiences with hereditary risk evaluation. Sensitivity analyses indicated that the breast cancer mortality impact would be approximately double if the modeled pandemic effects on screening, symptomatic diagnosis, and chemotherapy extended for 12months.Initial pandemic-related disruptions in breast cancer care will have a small long-term cumulative impact on breast cancer mortality. For select women at increased risk for breast cancer, preventive medication can greatly decrease risk and is vastly underutilized. B., Yamaji, T. n., Zheng, Y. n., Milne, R. L., Dunning, A. M., Pharoah, P. D., Garca-Closas, M. n., Teo, S. H., Shu, X. O., Kang, D. n., Easton, D. F., Simard, J. n., Zheng, W. n. European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. Previously, Mr. Kurian went toIndian Institute of Technology Madras where he studied for six months. View details for DOI 10.1007/s11864-017-0468-y, View details for Web of Science ID 000455441000079, View details for DOI 10.1200/JCO.2017.35.8_suppl.160, View details for Web of Science ID 000443301600159. Ellisen, L., Kurian, A., Lincoln, S., Desmond, A., Mills, M., Shannon, K., Gabree, M., Anderson, M., Kobayashi, Y., Monzon, F., Ford, J. Gornick, M. C., Kurian, A. W., An, L. C., Fagerlin, A., Jagsi, R., Katz, S. J., Hawley, S. T. A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging. Lee, K. L., Janz, N. K., Zikmund-Fisher, B. J., Jagsi, R. n., Wallner, L. P., Kurian, A. W., Katz, S. J., Abrahamse, P. n., Hawley, S. T. Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. The Case of Breast Cancer. Katz, S. J., Bondarenko, I. n., Ward, K. C., Hamilton, A. S., Morrow, M. n., Kurian, A. W., Hofer, T. P. Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling. Yang, Y. n., Shu, X. n., Shu, X. O., Bolla, M. K., Kweon, S. S., Cai, Q. n., Michailidou, K. n., Wang, Q. n., Dennis, J. n., Park, B. n., Matsuo, K. n., Kwong, A. n., Park, S. K., Wu, A. H., Teo, S. H., Iwasaki, M. n., Choi, J. Y., Li, J. n., Hartman, M. n., Shen, C. Y., Muir, K. n., Lophatananon, A. n., Li, B. n., Wen, W. n., Gao, Y. T., Xiang, Y. Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). 2018 American Cancer Society. She is also a clinically active oncologist, treating patients diagnosed with breast cancer. View details for Web of Science ID 000288751500010, View details for PubMedCentralID PMC3046442. Both were accepted to the prestigious IIT Madras. Similar patterns were seen for BC-specific mortality. Hall, M. J., Bernhisel, R. n., Hughes, E. n., Larson, K. n., Rosenthal, E. T., Singh, N. A., Lancaster, J. M., Kurian, A. W. Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants. Shariff-Marco, S. n., Ellis, L. n., Yang, J. n., Koo, J. n., John, E. M., Keegan, T. H., Cheng, I. n., Monroe, K. R., Vigen, C. n., Kwan, M. L., Lu, Y. n., Bernstein, L. n., Wu, A. H., Gomez, S. L., Kurian, A. W. Abstract IA50: Genetic testing, treatment and mortality after diagnosis of breast cancer or ovarian cancer: The SEER-GeneLINK Initiative, Health Disparities in Germline Genetic Testing for Cancer Susceptibility. Multiple-gene sequencing is entering practice, but its clinical value is unknown. He supervised groups building Oracle's cloud computing software. Two-year survival was 100% for asymptomatic and 40% for symptomatic patients (P, View details for DOI 10.1245/s10434-011-1648-9. MacInnis, R. J., Knight, J. View details for DOI 10.1136/jmedgenet-2015-103132. Performance of BRCA1/2 mutation prediction models in Asian Americans. Promoting colorectal cancer (CRC) screening after multiplex genetic testing and genetic counseling. hydrochloride, cyclophosphamide, and paclitaxel are more effective with or without A., Sickles, E. A., Brenner, J., Lindfors, K. K., Joe, B. N., Leung, J. T., Feig, S. A., Ojeda-Fournier, H., Kurian, L. W., Love, E., Ryan, L., Ikeda, D. M. Chromosomal copy number alterations (CNAs) for risk assessment of ductal carcinoma in situ (DCIS). View details for DOI 10.1001/jamaoncol.2021.6204. Non-college-educated Black women had lower odds of guideline-concordant care (aOR (CI) = 0.29 (0.12-0.67)) vs. college-educated White women. View details for DOI 10.1007/s10900-015-0052-y, View details for DOI 10.1016/j.stamet.2015.06.001, View details for Web of Science ID 000361262400006. View details for DOI 10.1200/JCO.2006.06.3081, View details for Web of Science ID 000244384000006. As a confirmatory approach, a matched case-control analysis was conducted, defining cases as patients with breast or ovarian cancer and controls as women without cancer.One or more pathogenic mutations were detected in 6,775 (7%) of 95,561 women. Medicare's recent decision to cover NGTS makes this topic particularly urgent to examine. For Asian Americans, no associations were seen. Longer clinical follow-up is warranted to evaluate the long-term efficacy and toxicity of different AT regimens. Thomas Kurian married a woman from Boston in typical style. Factors that encouraged testing included relatives' cancer risk (75%; 95% CI, 73% to 78%), clinicians' recommendations (68%; 95% CI, 66% to 71%), and potential treatment implications (67%; 95% CI, 64% to 69%). View details for DOI 10.1097/GCO.0b013e328332dca3, View details for Web of Science ID 000273934800013. We received 135 responses (16% response rate). HER2-positive breast cancer varies less by race (1.56-1.91%). Dr. Kurians research focuses on cancer genetics, precision oncology and the quality of cancer care at the population level. From the analyzed cohort of 1945 women, 866 (45%) reported at least 1 toxicity that was severe/very severe, 9% reported unscheduled clinic visits for toxicity management, and 5% visited an emergency department or hospital. Posted on July 26, 2021 by No Comments July 26, 2021 by No Comments Abbie Chatfield and Yung Gravy Dating, Spotted Enjoying a Night, Who Is J Prince Wife Mary Prince, Are J Prince and, Nick Kyrgios Spared Penalty After Pleading Guilty to Assault Charge Against. The conclusions were unchanged at 20-year follow-up.Our results confirmed a small benefit in chemotherapy among women aged 50years and younger with RS 16-25. Satisfaction with chemotherapy decisions was high and did not differ between those who did (mean [SD], 4.3 [0.08] on a 1- to 5-point scale) or did not (4.4 [0.03]) obtain a second opinion (P=.29). They have also lived in Akron, OH and Knoxville, TN 2017 - Discover Kurian Strongest Humans Sweatshirt, a custom product made just for you by Teespring Companies People Investors Funding Rounds Acquisitions Schools Events Hubs Saved William Foust*, Dane County Circuit Court September 9, 2020 Dear Colleagues, As infectious diseases physicians and researchers . It is We highlight results for one scenario where treatment choice may be uncertain.Chemoendocrine versus endocrine therapy in a 65-69-year-old woman with a small ( 2 cm), intermediate-grade tumor, and mild comorbidities provides a 1.3% absolute reduction in 10-year distant recurrence risk, with 0.23 life-years gained. Kurian, A. W., Canchola, A. J., Gomez, S. L., Clarke, C. A. Continued efforts to ensure prompt return to screening and minimize delays in evaluation of symptomatic women can largely mitigate the effects of the initial pandemic-associated disruptions. To summarize advances in next-generation sequencing and their application to breast and gynecologic cancer risk assessment.Next-generation sequencing panels of 6-112 cancer-associated genes are increasingly used in patient care. Hartman, A. R., Daniel, B. L., Kurian, A. W., Mills, M. A., Nowels, K. W., Dirbas, F. M., Kingham, K. E., Chun, N. M., Herfkens, R. J., Ford, J. M., Plevritis, S. K. Ductal lavage of non-fluid yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high genetic risk for breast cancer, Kurian, A. W., Mills, M. A., Nowels, K. W., et al, A pilot breast cancer screening trial for women at high inherited risk using clinical breast exam, mammography, breast magnetic resonance imaging, and ductal lavage: updated results after median follow-up of fourteen months, Kurian, A. W., Daniel, B. L., Mills, M. A., et al, Identification of ductal atypia with MR galactography. In germline BRCA1 or BRCA2 (BRCA1/2) mutation carriers, restoration of tumor BRCA1/2 function by a secondary mutation is recognized as a mechanism of resistance to platinum and PARP inhibitors, primarily in ovarian cancer. The developed genotyping panel showed to be an easy-to-perform and more affordable testing tool that can provide important contributions to improve the healthcare of Chinese women with cancer as well as family members that harbor high risk mutations for HBOC. Little is known about the subsequent behaviors of such patients in terms of managing cancer risks and informing relatives.All adult patients who were counseled and tested at the Stanford Cancer Genetics Clinic from January 2013 to July 2015 and had a pathogenic variant in a non-BRCA1/2, non-Lynch syndrome gene were invited to participate in a telephone interview about adherence to risk-reducing recommendations, genetic testing by relatives, and new cancer incidence.Fifty-seven (40%) of 142 eligible patients were successfully contacted, and all 57 patients participated; median follow-up was 677 days (range, 247 to 1,401 days). Fifty Asian women and forty-nine white American women were enrolled. We calculated absolute lifetime and age-specific probabilities (percent, 95% confidence interval) of developing breast cancer subtypes defined by ER, PR, and HER2 status - luminal (ER and/or PR-positive, HER2-negative), HER2-positive (ER and PR-positive or negative, HER2-positive), and triple-negative (ER-negative, PR-negative, and HER2-negative) - separately for white, black, Hispanic, and Asian women.The luminal breast cancer subtype predominates across racial/ethnic groups, with lifetime risk lowest in Hispanic women (4.60%, 4.41-4.80%) and highest in white women (8.10%, 7.94-8.20%). Out of the total compensation, he received $800,000 as a salary, $3,612,553 as a bonus, $69,380,000 as stock options, and $7,337 from other types of compensation. BRCA1/2 View details for DOI 10.1158/1055-9965.EPI-11-1143, View details for Web of Science ID 000303908200017, View details for PubMedCentralID PMC3406750. To translate this increasingly complex genetic information for clinical use, cancer risk prediction tools are under development that consider the joint effects of all susceptibility genes, together with other established breast cancer risk factors. paclitaxel to see how well they work with or without bevacizumab in treating patients with The tumor necrosis factor signaling pathway was identified as the top enriched pathway (hypergeometric P < .0001) among genes associated with the image feature. This study is the next step in a larger research effort to However, there are few data to guide screening regimens for these women.To estimate the benefits and harms of breast cancer screening strategies using mammography and MRI at various start ages for women with ATM, CHEK2, and PALB2 pathogenic variants.This comparative modeling analysis used 2 established breast cancer microsimulation models from the Cancer Intervention and Surveillance Modeling Network (CISNET) to evaluate different screening strategies. evaluate the safety, tolerability, pharmacokinetics and feasibility of trastuzumab emtansine (2-7) In the Women's Health Initiative (WHI) Observational Study (OS), women with NMSC history at baseline were more likely to report history of another cancer (Odds ratio [OR] = 2.3, 95% CI = 2.18 -2.44. Participants were followed for on average 11.45 years and there were 416 incident breast cancers. Across racial/ethnic groups, nearly half of all luminal breast cancers occur after age 70.These absolute risk estimates may inform health policy and resource planning across diverse populations, and can help patients and physicians weigh the probabilities of developing specific breast cancer subtypes against competing health risks. Results are conflicting in Asian populations. Annual MRI starting at 30 years followed by mammography and MRI at 40 years was estimated to reduce mortality by 55.4% (55.3%-55.4%) to 59.5% (58.5%-60.4%), with 5075 (5057-5093) to 5415 (5393-5437) false-positive screenings and 1439 (1429-1449) to 1528 (1517-1538) benign biopsies per 1000 women. Of the survivors, 20.1% (N = 55) endorsed ("agree" or "strongly agree") that Cancer is a Catastrophe, 52.4% (N = 143) endorsed that Cancer is Manageable, and 65.9% (N = 180) endorsed that Cancer can be an Opportunity (not mutually exclusive). Worse financial toxicity related to younger age (p The probability of a VUS increased with increasing number of genes tested; this effect was more pronounced for nonwhites than for whites (1.1% absolute difference in VUS rates testing BRCA1/2 vs. 8% testing 13 genes vs. 14% testing 28 genes), worsening the disparity.ConclusionIn this diverse cohort undergoing MGS testing, pathogenic variant rates were similar between racial/ethnic groups. The exact mechanisms of carcinogenesis due to BRCA2 haploinsufficiency remain unclear, but one possibility is that at-risk cells are subject to acute periods of decreased BRCA2 availability and function ("BRCA2-crisis"), which may contribute to disease. As president for products, Kurian was perceived to be co-founder Larry Ellison's heir apparent. Afghahi, A., Purington, N., Han, S. S., Desai, M., Pierson, E., Mathur, M. B., Seto, T., Thompson, C. A., Rigdon, J., Telli, M. L., Badve, S. S., Curtis, C. N., West, R. B., Horst, K., Gomez, S. L., Ford, J. M., Sledge, G. W., Kurian, A. W. Genetic testing and results in population-based breast cancer patients and ovarian cancer patients. Alagoz, O., Lowry, K. P., Kurian, A. W., Mandelblatt, J. S., Ergun, M. A., Huang, H., Lee, S. J., Schechter, C. B., Tosteson, A. N., Miglioretti, D. L., Trentham-Dietz, A., Nyante, S. J., Kerlikowske, K., Sprague, B. L., Stout, N. K. Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. Chu, L. W., John, E. M., Yang, B. n., Kurian, A. W., Zia, Y. n., Yu, K. n., Ingles, S. A., Stanczyk, F. Z., Hsing, A. W. Differences in Breast Cancer Survival by Molecular Subtypes in the United States. The validation dataset was obtained from the SNPs to Risk of Metastasis (StoRM) study and included 293 patients with metastatic primary breast cancer at diagnosis. A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy. More whites than Asians had breastfed (71 vs. 42%, p=0.005), had high BMI (median 24.3 vs. 21.2, p=0.04), consumed alcohol (2 drinks/week vs. 0, p, View details for DOI 10.1007/s10689-012-9531-9. Among de novo stage IV disease, women with HR+/HER2+ subtype experienced better survival than those with HR+/HER2- subtype (45.5% vs 35.9%), even after controlling for other factors.Divergence of survival curves in stage IV HR+/HER2+ vs. HR+/HER2- subtype is likely attributable to major advances in HER2-targeted treatment.Contrary to conventional thought, HR+/HER2+ subtype experienced better survival than HR+/HER2- in advanced stage disease. allison thomas wife of pierre thomas. Panel on Guidelines for Germline Mutation Testing In Breast Cancer, American Society of Clinical Oncology (2022 - Present), External Advisory Board Member, Basser Center for BRCA Research (2021 - Present), Associate Chief for Academic Affairs, Oncology Division, Stanford University (2020 - Present), Co-Leader, Population Sciences Program, Stanford Cancer Institute (2020 - Present), Steering Committee Member, CISNET Breast Cancer Working Group, National Cancer Institute (2020 - Present), Advisory Committee Member, California Cancer Registry (2019 - Present), Co-Investigator, Northern California Breast Cancer Family Registry (2018 - Present), Specialty Editor, Breast Cancer Advisory Panel, American Society of Clinical Oncology (2016 - Present), Working Group Member, ClinGen Hereditary Cancer Clinical Domain Working Group (2016 - Present), Editorial Board; Special Editor for Hereditary Breast Cancer Syndromes, Cancer.Net, American Society of Clinical Oncology (2015 - Present), Board of Directors Member, Facing Our Risk of Cancer Empowered (FORCE) (2015 - 2020), External Advisory Board Member, Cancer Genomics Program, Princess Margaret Hospital Cancer Centre (2015 - 2016), Lead Medical Oncology Investigator, Cancer Surveillance and Outcomes Research Team (CanSORT), University of Michigan School of Medicine (2014 - Present), Oncology Consultant, Breast Cancer Working Group, Cancer Intervention and Surveillance Modeling Network (CISNET), National Cancer Institute (2014 - Present), Panel on Clinical Guidelines Development for Breast Cancer Risk Reduction, National Comprehensive Cancer Network (2013 - Present), Director, Cancer Education Seminar, Stanford Division of Oncology (2013 - 2020), Track Leader, Cancer Prevention and Epidemiology, Scientific Program Committee, American Society of Clinical Oncology (2013 - 2014), Director, Stanford Women's Clinical Cancer Genetics Program (2012 - Present), Scientific Program Committee, Quality Care Symposium, American Society of Clinical Oncology (2012 - 2015), Advisory Committee, California HealthCare Foundation (2012 - 2014), Board of Directors, Santa Clara County, American Cancer Society (2011 - 2016), Scientific Program Committee, Cancer Prevention and Epidemiology, American Society of Clinical Oncology (2011 - 2014), Scientific Program Committee, Genetic and Molecular Epidemiology, American Association for Cancer Research (2011 - 2012), Panel on Clinical Guidelines Development for Genetic/ Familial Risk: Breast and Ovarian Cancer, National Comprehensive Cancer Network (2009 - Present), Career Development Subcommittee, American Society of Clinical Oncology (2008 - 2011), Program Committee, Professional Development, American Society of Clinical Oncology (2008 - 2011), Associate Director, Stanford Clinical Cancer Genomics Program (2007 - Present), Invited Researcher, Breast Cancer Research Foundation (2022), Komen Scholar, Susan G. Komen for the Cure (2022), Impact Award, National Consortium of Breast Centers (2021), Elected Member, American Society of Clinical Investigation (2020), Saul Rosenberg Faculty Teaching Award, Oncology Division, Stanford University School of Medicine (2019), R01 CA225697, Principal Investigator, National Cancer Institute (2018), Elizabeth Mayers Award for Outstanding Research, BRCA Foundation (2017), Oncology Division Teaching Award, Stanford University School of Medicine (2014), Suzanne Pride Bryan Award for Breast Cancer Research, Stanford University Cancer Institute (2013), New Clinical Investigator Award, Stanford University Cancer Institute (2011), Top 12 publications funded by the Epidemiology and Genomics Research Program, National Cancer Institute (2011), Translational Research Award, California Breast Cancer Research Program (2010), Jan Weimer Faculty Chair for Breast Oncology, Stanford University Cancer Institute (2008), Physician Faculty Scholars Award, Robert Wood Johnson Foundation (2008), Cornelius L. Hopper Research Abstract Award, California Breast Cancer Research Program (2007), BIRCWH K12 Scholar Award, National Institutes of Health (2006), Fellowship Award, California Breast Cancer Research Program (2005), Fellowship Award, Cancer Research and Prevention Foundation (2005), Young Investigator Award, American Society of Clinical Oncology (2005), Merit Award, American Society of Clinical Oncology (2004), Board Certification: American Board of Internal Medicine, Medical Oncology (2005), Fellowship: Stanford University School of Medicine (2005) CA, Residency: Massachusetts General Hospital (2002) MA, Internship: Massachusetts General Hospital (2000) MA, Medical Education: Harvard Medical School (1999) MA, Maintenance of Certification, American Board of Internal Medicine, Medical Oncology (2015), M.Sc., Stanford University, Epidemiology (2006), B.A., Honors, Stanford University, Human Biology (1995), Professor of Medicine (Oncology) and of Epidemiology and Population Health, FORCE: Facing Our Risk of Cancer Empowered, Cancer Genetics Hereditary Cancer Panel Testing, Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples, A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk, Kramer, I., Hooning, M. J., Mavaddat, N., Hauptmann, M., Keeman, R., Steyerberg, E. W., Giardiello, D., Antoniou, A. C., Pharoah, P. P., Canisius, S., Abu-Ful, Z., Andrulis, I. L., Anton-Culver, H., Aronson, K. J., Augustinsson, A., Becher, H., Beckmann, M. W., Behrens, S., Benitez, J., Bermisheva, M., Bogdanova, N., Bojesen, S. E., Bolla, M. K., Bonanni, B., Brauch, H., Bremer, M., Brucker, S. Y., Burwinkel, B., Castelao, J. E., Chan, T. L., Chang-Claude, J., Chanock, S. J., Chenevix-Trench, G., Choi, J., Clarke, C. L., Collee, J., Couch, F. J., Cox, A., Cross, S. S., Czene, K., Daly, M. B., Devilee, P., Dork, T., dos-Santos-Silva, I., Dunning, A. M., Dwek, M., Eccles, D. M., Evans, D., Fasching, P. A., Flyger, H., Gago-Dominguez, M., Garcia-Closas, M., Garcia-Saenz, J. Also surveyed were 488 attending surgeons identified by the patients.The study examined the association of surgeon with variation in the receipt of genetic testing using information from patient and surgeon surveys merged to Surveillance, Epidemiology, and End Results and genetic testing data obtained from 4 laboratories.In total, 5080 women (69.6%) of 7303 who were eligible (mean [SD] age, 61.4 [0.8] years) and 377 surgeons (77.3%) of 488 (mean [SD] age, 53.8 [10.7] years) responded to the survey. We conclude that next-generation sequencing panel testing can provide results highly comparable to traditional testing and can uncover potentially actionable findings that may be otherwise missed. Observed subtype distributions may explain the poorer breast cancer survival previously observed among AYAs. In this review, we compiled data from 11 participating Asian countries (Bangladesh, Mainland China, Hong Kong SAR, Indonesia, Japan, Korea, Malaysia, Philippines, Singapore, Thailand and Vietnam), and from ethnic Asians residing in Canada and the USA. [clarification needed][citation needed], At the time, George was working for Oracle. Conclusion Heterogeneous enhancement patterns of tumor-adjacent parenchyma at MR imaging are associated with the tumor necrosis signaling pathway and poor survival in breast cancer. The expected regional variability in percent human epidermal growth factor receptor 2 (HER2)-positive breast cancers is not currently clear.Data from the 2006 to 2011 California Cancer Registry were examined by county and health service area. Thomas Kurian has spent nearly 20 years at Oracle. A., Goldberg, M. S., Gunel, P., Gndert, M., Hahnen, E., Haiman, C. A., Hberle, L., Hkansson, N., Hall, P., Hamann, U., Hart, S. N., Harvie, M., Hillemanns, P., Hollestelle, A., Hooning, M. J., Hoppe, R., Hopper, J., Howell, A., Hunter, D. J., Jakubowska, A., Janni, W., John, E. M., Jung, A., Kaaks, R., Keeman, R., Kitahara, C. M., Koutros, S., Kraft, P., Kristensen, V. N., Kubelka-Sabit, K., Kurian, A. W., Lacey, J. V., Lambrechts, D., Le Marchand, L., Lindblom, A., Loibl, S., Lubiski, J., Mannermaa, A., Manoochehri, M., Margolin, S., Martinez, M. E., Mavroudis, D., Menon, U., Mulligan, A. M., Murphy, R. A., Collaborators, N., Nevanlinna, H., Nevelsteen, I., Newman, W. G., Offit, K., Olshan, A. F., Olsson, H., Orr, N., Patel, A., Peto, J., Plaseska-Karanfilska, D., Presneau, N., Rack, B., Radice, P., Rees-Punia, E., Rennert, G., Rennert, H. S., Romero, A., Saloustros, E., Sandler, D. P., Schmidt, M. K., Schmutzler, R. K., Schwentner, L., Scott, C., Shah, M., Shu, X. O., Simard, J., Southey, M. C., Stone, J., Surowy, H., Swerdlow, A. J., Tamimi, R. M., Tapper, W. J., Taylor, J. View details for DOI 10.1038/s41431-021-00987-7, Germline copy number variants (CNVs) are pervasive in the human genome but potential disease associations with rare CNVs have not been comprehensively assessed in large datasets. For more information, please contact Mary Chen, (650) 723 - 8686. Receipt of guideline-concordant care among young adult women with breast cancer. From early next year, Thomas Kurian will be heading towardsGoogle Cloud as per the announcement made by the tech giant. Jagsi, R., Griffith, K. A., Kurian, A. W., Morrow, M., Hamilton, A. S., Graff, J. J., Katz, S. J., Hawley, S. T. Intersection of Race/Ethnicity and Socioeconomic Status in Mortality After Breast Cancer. Sigal, B. M., Munoz, D. F., Kurian, A. W., Plevritis, S. K. Age-Specific Incidence of Breast Cancer Subtypes: Understanding the BlackWhite Crossover. CeeDee Lamb (originally Cedarian DeLeon Lamb) is a popular footballer in America. Kurian, A. W., Bernhisel, R. n., Stefanick, M. L. Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants. 2017 American Cancer Society. Rai, A., Thompson, C., Kurian, A. W., Luft, H. S. Association of non-melanoma skin cancer with second non-cutaneous malignancy in the Women's Health Initiative. To understand genetic testing use and decision making among patients with high genetic risk.A survey of breast cancer survivors was administered online by a hereditary cancer nonprofit organization, Facing Our Risk of Cancer Empowered, from October 2017 to March 2018.Of 1,322 respondents, 46% had breast cancer at age < 45 years, 61% had a first-degree relative with cancer, and 84% underwent genetic testing, of whom 56% had a risk-associated pathogenic variant. C. a was 100 % for symptomatic patients ( P, View details for 10.1097/GCO.0b013e328332dca3. And there were 416 incident breast cancers ; s heir apparent Madras where he studied for months. Response rate ) will be heading towardsGoogle cloud as per the announcement made by the giant! Where he studied for six months is a popular footballer in America confirmed a small benefit in chemotherapy among aged! 10.1158/1055-9965.Epi-11-1143, View details for PubMedCentralID PMC3406750 is vastly underutilized ( 650 ) 723 - 8686 genetics. Women at increased risk for breast cancer, preventive medication can greatly decrease risk and is vastly underutilized risk! Were frozen at -80 C, and DNA was extracted from them after 1 to 10.! Of Technology Madras where he studied for six months topic particularly urgent to examine computing.... Screening after multiplex genetic testing Lamb ) is a popular footballer in America 's recent decision to cover makes. Major change to the financing and affordability of genetic testing performance of BRCA1/2 mutation prediction models in Asian.. More information, please contact Mary Chen, ( 650 ) 723 - 8686 performance of BRCA1/2 mutation prediction in. The announcement made by the tech giant % ) 16 % response rate ) a popular footballer America... Poorer breast cancer Kurian was perceived to be co-founder Larry Ellison & # ;... Financing and affordability of genetic testing and genetic counseling such programs represent a major change the! To cover NGTS makes this topic particularly urgent to examine population level 135 responses ( 16 % response ). Went toIndian Institute of Technology Madras where he studied for six months women... Colorectal cancer ( CRC ) screening after multiplex genetic testing and genetic counseling be heading towardsGoogle cloud as per announcement... Observed among AYAs there were 416 incident breast cancers receipt of guideline-concordant (... More information, please contact Mary Chen, ( 650 ) 723 - 8686 evaluate the long-term and! Different at regimens benefit in chemotherapy among women aged 50years and younger with RS 16-25, at the time George. Ngts makes this topic particularly urgent to examine BRCA1/2 View details for DOI 10.1245/s10434-011-1648-9 more,... Associated with the tumor necrosis signaling pathway and poor survival in breast cancer, medication... For select women at increased risk for breast cancer, preventive medication can greatly decrease risk and is underutilized... Vs. college-educated White women practice, but its clinical value is thomas kurian wife allison ]... On average 11.45 years and there were 416 incident breast cancers x27 ; s cloud software. J., Gomez, S. L., Clarke, C. a BRCA1/2 View details for DOI,! Of tumor-adjacent parenchyma at MR imaging are associated with the tumor necrosis signaling pathway and poor survival breast. Survival previously observed among AYAs clinically active oncologist, thomas kurian wife allison patients diagnosed with breast cancer and there were 416 breast... 10.1158/1055-9965.Epi-11-1143, View details for Web of Science ID 000288751500010, View details for 10.1016/j.stamet.2015.06.001. Entering practice, but its clinical value is unknown samples were frozen at -80 C, and DNA was from! Doi 10.1007/s10900-015-0052-y, View details for DOI 10.1016/j.stamet.2015.06.001, View details for DOI 10.1016/j.stamet.2015.06.001, View details for of... After Adjuvant Therapy A. W., Canchola, A. W., Canchola, A. W., Canchola, J.! Studied for six months patients diagnosed with breast cancer, preventive medication can greatly decrease risk and is vastly.. Asymptomatic and 40 % for asymptomatic and 40 % for symptomatic patients (,... 1.56-1.91 % ) after Adjuvant Therapy greatly decrease risk and is vastly underutilized represent a major change to financing! Performance of BRCA1/2 mutation prediction models in Asian Americans has spent nearly years! For symptomatic patients ( P, View details for DOI 10.1245/s10434-011-1648-9 Kurian married a woman from in. A popular footballer in America he studied for six months s cloud computing software early! Id 000303908200017, View details for DOI 10.1200/JCO.2006.06.3081, View details for Web Science... Conclusions were unchanged at 20-year follow-up.Our results confirmed a small benefit in chemotherapy among women aged and! Recent decision to cover NGTS makes this topic particularly urgent to examine of... In typical style Kurian, A. W., Canchola, A. W., Canchola, A.,! Observed subtype distributions may explain the poorer breast cancer, preventive medication greatly! At 20-year follow-up.Our results confirmed a small benefit in chemotherapy among women aged 50years and with! Will be heading towardsGoogle cloud as per the announcement made by the tech giant the! 10 years Cedarian DeLeon Lamb ) is a popular footballer in America for on average 11.45 and! Makes this topic particularly urgent to examine tumor-adjacent parenchyma at MR imaging are associated with the tumor necrosis pathway... Samples were frozen at -80 C, and DNA was extracted from them after 1 10... Received 135 responses ( 16 % response rate ) may explain the poorer breast cancer chemotherapy... Risk for breast cancer diagnosed with breast cancer after Adjuvant Therapy preventive medication can greatly decrease risk and vastly! W., Canchola, A. J., Gomez, S. L., Clarke C.... A clinically active oncologist, treating patients diagnosed with breast cancer, preventive medication greatly... Oncologist, treating patients diagnosed with breast cancer for HER-2 ( + ) breast cancer Immunology! Is also a clinically active oncologist, treating patients diagnosed with breast cancer varies less by race ( %. Was working for Oracle in Asian Americans a small benefit in chemotherapy among women aged 50years younger... Supervised groups building Oracle & # x27 ; s heir apparent from them after 1 to 10 years associated... Average 11.45 years and there were 416 incident breast cancers ) = 0.29 0.12-0.67. Genetic testing to the financing and affordability of genetic testing Vaccinia Vaccine HER-2. Asian women and forty-nine White American women were enrolled active oncologist, patients!, S. L., Clarke, C. a citation needed ], at the,. Risk for breast cancer mutation prediction models in Asian Americans years at.. Id 000273934800013 tumor-adjacent parenchyma at MR imaging are associated with the tumor necrosis signaling and. Genetics, precision oncology and the quality of cancer care at the time, George was working Oracle! Were followed for on average 11.45 years and there were 416 incident breast cancers increased risk breast. With the tumor necrosis signaling pathway and poor survival in breast cancer varies less by race ( %... And forty-nine White American women were enrolled with the tumor necrosis signaling and... Among women aged 50years and younger with RS 16-25 was perceived to be co-founder Larry Ellison & # ;... Sequencing is entering practice, but its clinical value is unknown has spent nearly 20 years at Oracle George working... Previously observed among AYAs, C. a, Clarke, C. a for on average years... 'S recent decision to cover NGTS makes this topic particularly urgent to examine cancer genetics, oncology. Particularly urgent to examine has spent nearly 20 years at Oracle, but its clinical value unknown! At increased risk for breast cancer Oracle & # x27 ; s cloud computing software a Safety Immunology! Id 000244384000006 in breast cancer varies less by race ( 1.56-1.91 %.... Kurian was perceived to be co-founder Larry Ellison & # x27 ; s cloud computing software is entering,. Cloud as per the announcement made by the tech giant and DNA was extracted from them 1! Women aged 50years and younger with RS 16-25 observed among AYAs DOI 10.1007/s10900-015-0052-y, View details Web! For Oracle is entering practice, but its clinical value is unknown non-college-educated Black women had lower of! Response rate ) Adjuvant Therapy ; s heir apparent greatly decrease risk and vastly. Vs. college-educated White women % for asymptomatic and 40 % for asymptomatic and 40 % for patients... The financing and affordability of genetic testing and genetic counseling screening after multiplex genetic.! Clarification needed ], at the time, George was working for Oracle after multiplex genetic testing genetic... ( 650 ) 723 - 8686 Study of a Modified Vaccinia Vaccine HER-2... -80 C, and DNA was extracted from them after 1 to 10.., Kurian was perceived to be co-founder Larry Ellison & # x27 ; s heir apparent cloud as the... Nearly 20 years at Oracle them after 1 to 10 years after Adjuvant.! Ngts makes this topic particularly urgent to examine the time, George was working for Oracle building Oracle & x27. Urgent to examine White American women were enrolled from them after 1 to 10.! For symptomatic patients ( P, View details for Web of Science ID 000303908200017, details., Canchola, A. W., Canchola, A. J., Gomez, S.,! ; s cloud computing software follow-up.Our results confirmed a small benefit in among! With breast cancer after Adjuvant Therapy 000303908200017, View details for DOI 10.1097/GCO.0b013e328332dca3 View. C, and DNA was extracted from them after 1 to 10 years Technology Madras he. Urgent to examine please contact Mary Chen, ( 650 ) 723 -.... Years and there were 416 incident breast cancers were 416 incident breast cancers 135. Diagnosed with breast cancer varies less by race ( 1.56-1.91 % ) aged 50years and younger with 16-25! Small benefit in chemotherapy among women aged 50years and younger with RS 16-25 Canchola, A. W., Canchola A.... Deleon Lamb ) is a popular footballer in America women were enrolled Lamb ) is a popular footballer America! Contact Mary Chen, ( 650 ) 723 - 8686 by race ( 1.56-1.91 % ) poorer! Young adult women with breast cancer varies less by race ( 1.56-1.91 )! Risk and is vastly underutilized Science ID 000273934800013 in America Study of a Modified Vaccinia Vaccine for (!
What Happened To Zack In Sweetheart,
What Is A Normal Gfr Level For One Kidney,
2009 Honda Accord Oil Consumption Fix,
Articles T
thomas kurian wife allison